Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H19N3O2 |
Molecular Weight | 261.3196 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N[C@@H]1CCN2C(=O)NC3=CC=CC([C@H]1O)=C23
InChI
InChIKey=ZSTCZWJCLIRCOJ-DGCLKSJQSA-N
InChI=1S/C14H19N3O2/c1-8(2)15-11-6-7-17-12-9(13(11)18)4-3-5-10(12)16-14(17)19/h3-5,8,11,13,15,18H,6-7H2,1-2H3,(H,16,19)/t11-,13-/m1/s1
Molecular Formula | C14H19N3O2 |
Molecular Weight | 261.3196 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.fao.org/fileadmin/user_upload/vetdrug/docs/15-2013-zilpaterol-hydrochloride.pdfCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3240917
Sources: http://www.fao.org/fileadmin/user_upload/vetdrug/docs/15-2013-zilpaterol-hydrochloride.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3240917
Zilpaterol is an agonist of β2-adrenergic receptor. Zilpaterol exerts bronchospasmolytic action. Zilmax® (4.8% Zilpaterol hydrochloride) is used to increase rate of bodyweight gain, improve feed efficiency, and increase carcass leanness in cattle fed in confinement for a period of 20-40 consecutive days at the end of the feeding period before slaughter.
Originator
Sources: Frechet D., Plassard G., Brown N.L., Cltmence F., Nhdelec L. & Worcel M. (1984) Proceedings of the VlIIth International Symposium on Medicinal Chemistry, Swedish Pharmaceutical Press, Stockholm. Vol. I , pp. 90-93
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/3240917
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 |
1.1 µM [Ki] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16343285 |
10.0 µM [Ki] | ||
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19245211 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Enzyme-linked immunosorbent assay development for the beta-adrenergic agonist zilpaterol. | 2004 Apr 21 |
|
Characterization of anti-inflammatory compounds using transcriptomics, proteomics, and metabolomics in combination with multivariate data analysis. | 2004 Nov |
|
Beta-adrenergic receptor agonists induce the release of granulocyte chemotactic protein-2, oncostatin M, and vascular endothelial growth factor from macrophages. | 2006 Jan |
|
Dietary zilpaterol hydrochloride. I. Feedlot performance and carcass traits of steers and heifers. | 2009 Apr |
|
Dietary zilpaterol hydrochloride. II. Carcass composition and meat palatability of beef cattle. | 2009 Apr |
|
Effects of zilpaterol hydrochloride on growth rates, feed conversion, and carcass traits in calf-fed Holstein steers. | 2009 Dec |
|
Effects of implanting and feeding zilpaterol hydrochloride on performance, carcass characteristics, and subprimal beef yields of fed cows. | 2009 Feb |
|
Effects of dietary zilpaterol hydrochloride on feedlot performance and carcass characteristics of beef steers fed with and without monensin and tylosin. | 2009 Mar |
|
Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol. | 2009 Mar 26 |
|
Effects of preslaughter withdrawal period on response of feedlot heifers to zilpaterol hydrochloride supplementation: growth performance and carcass characteristics. | 2009 May |
|
Effect of feeding zilpaterol hydrochloride to beef and calf-fed Holstein cattle on consumer palatability ratings. | 2009 Nov |
|
Effects of zilpaterol hydrochloride and zilpaterol hydrochloride withdrawal time on beef carcass cutability, composition, and tenderness. | 2009 Nov |
|
Effects of duration of zilpaterol hydrochloride and days on the finishing diet on carcass cutability, composition, tenderness, and skeletal muscle gene expression in feedlot steers. | 2009 Nov |
|
Effects of duration of zilpaterol hydrochloride supplementation on growth performance, carcass traits and meat quality of grain-fed cull cows. | 2010 Apr |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
[Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry]. | 2010 Aug |
|
Effect of extended withdrawal of zilpaterol hydrochloride on performance and carcass traits in finishing beef steers. | 2010 Jan |
|
The effects of zilpaterol hydrochloride on carcass cutability and tenderness of calf-fed Holstein steers. | 2010 Jul |
|
Effects of supplementing feedlot steers and heifers with zilpaterol hydrochloride on Warner-Bratzler shear force interrelationships of steer and heifer longissimus lumborum and heifer triceps brachii and gluteus medius muscles aged for 7, 14 and 21d. | 2010 Jun |
|
Effect of zilpaterol hydrochloride supplementation on cutability and subprimal yield of beef steer carcasses. | 2010 May |
|
Moisture enhancement and blade tenderization effects on the shear force and palatability of strip loin steaks from beef cattle fed zilpaterol hydrochloride. | 2010 May |
|
Comparative effects of ractopamine hydrochloride and zilpaterol hydrochloride on growth performance, carcass traits, and longissimus tenderness of finishing steers. | 2010 May |
|
The efficiency of electrical stimulation to counteract the negative effects of β-agonists on meat tenderness of feedlot cattle. | 2010 Nov |
Sample Use Guides
Zilmax® (4.8% Zilpaterol hydrochloride) is used to increase rate of bodyweight gain, improve feed efficiency, and increase carcass leanness in cattle fed in confinement for a period of 20-40 consecutive days at the end of the feeding period before slaughter. Zilpaterol hydrochloride should be mixed into the feed at a level of 7.5 mg/kg on a 90% dry matter basis. This represents a dose of approximately 0.15 mg/kg bw or 60 to 90 mg
zilpaterol hydrochloride per animal per day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22079997
Zilpaterol hydrochloride at 1 µM decreased β1-adrenergic receptor mRNA, and 0.01 and 1 µM Zilpaterol hydrochloride decreased β2-adrenergic receptor and β3-adrenergic receptor mRNA in bovine myoblasts.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:29:15 GMT 2023
by
admin
on
Fri Dec 15 15:29:15 GMT 2023
|
Record UNII |
S384A1Y12J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 558.665
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
||
|
CFR |
21 CFR 556.765
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID50904261
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
ZILPATEROL
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
S384A1Y12J
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
3086576
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
119520-05-7
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
117827-79-9
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
SUPERSEDED | |||
|
C74221
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
SUB00158MIG
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL2218907
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
100000079046
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
1727538
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | RxNorm | ||
|
6349
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | |||
|
m11594
Created by
admin on Fri Dec 15 15:29:15 GMT 2023 , Edited by admin on Fri Dec 15 15:29:15 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |